ReviewPharmacogenomics2019
Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.
Review in Pharmacogenomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- ACKR1/Duffy-null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Meta-analyses of clozapine, norclozapine levels and their ratio across three genome wide association studies.Translational psychiatry · 2025Pooled it
- Pooled it
- A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.CNS drugs · 2022Guideline
- Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study.Translational psychiatry · 2021Pooled it
- Analytic Misjudgment of Drug Safety Evidence and Causality: From the Prosecutor's Fallacy and Simpson's Paradox to Artificial Intelligence.Drug safety · 2026Review
- Overview of the DREADDs chemogenetics and the patent landscape of their actuators.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Association between initial 30-day cumulative clozapine dose and risk of agranulocytosis: A nationwide register-based cohort study.Psychiatry and clinical neurosciences · 2026Article
- Late-Onset Neutropenia in Clozapine Users: Unrelated or Drug-Induced? A Case-Registry Analysis of Incidence, Characteristics, and Rechallenge Attempts.Schizophrenia bulletin · 2026Article
- Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system.Therapeutic advances in psychopharmacology · 2026Article
- Polygenic overlap with granulocyte counts identifies novel loci for clozapine metabolism and clozapine-induced agranulocytosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Secondary Neutropenias.Biomedicines · 2025Review
- Longitudinal changes in DNA methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts.Translational psychiatry · 2024Article
- Decoding Clozapine-Induced Agranulocytosis: Unraveling Interactions and Mitigation Strategies.Pharmacy (Basel, Switzerland) · 2024Article
- Can lithium be used in the setting of clozapine commencement in patients with COVID-19 associated neutropenia: A case report.Clinical case reports · 2024Article
- Agranulocytosis Associated With Psychiatric Polypharmacy: Lessons Learned From a Clinical Case.Cureus · 2024Article
- Polymorphisms and Pharmacogenomics ofGenes · 2024Review
- Clozapine-Induced Chemogenetic Neuromodulation Rescues Post-Stroke Deficits After Chronic Capsular Infarct.Translational stroke research · 2023Article
- The Role of Myeloperoxidase in Clozapine-Induced Inflammation: A Mechanistic Update for Idiosyncratic Drug-Induced Agranulocytosis.International journal of molecular sciences · 2023Article
- Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.Translational psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neutropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7. We describe recent findings relating to the Duffy-null genotype and its association with benign neutropenia in individuals with African ancestry. Further advances will come from sequencing studies, large, cross-population studies and in understanding the molecular mechanisms underlying these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.